|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquired_by
|
gptkb:Amgen
|
|
gptkbp:ceo
|
Tim Walbert
|
|
gptkbp:clinical_trial
|
Ongoing
|
|
gptkbp:focus_area
|
Autoimmune diseases
|
|
gptkbp:founded_in
|
gptkb:2012
|
|
gptkbp:global_presence
|
gptkb:Yes
|
|
gptkbp:headcount
|
Approximately 1,000
|
|
gptkbp:headquarters
|
gptkb:London,_United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Horizon Therapeutics UK Ltd.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:mission
|
To deliver innovative medicines.
|
|
gptkbp:number_of_employees
|
1000+
|
|
gptkbp:partnerships
|
Various healthcare organizations
|
|
gptkbp:products
|
gptkb:Krystexxa
gptkb:Tepezza
Uplizna
|
|
gptkbp:research_and_development
|
gptkb:Yes
|
|
gptkbp:specializes_in
|
Rare diseases
|
|
gptkbp:stock_symbol
|
gptkb:HZNP
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:values
|
gptkb:Innovation
gptkb:collaboration
gptkb:government_agency
Integrity
Excellence
|
|
gptkbp:vision
|
Transforming the lives of patients.
|
|
gptkbp:website
|
www.horizontherapeutics.com
|
|
gptkbp:bfsParent
|
gptkb:Horizon_Therapeutics
|
|
gptkbp:bfsLayer
|
5
|